* subjects who cannot orally administer the investigational products * subjects who need administration of immunosuppressants * subjects who are allergic or sensitive to investigational products or its ingredients * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

* subjects who cannot orally administer the investigational products * subjects who need administration of immunosuppressants * subjects who are allergic or sensitive to investigational products or its ingredients * subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening * subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

- subjects who cannot orally administer the investigational products - subjects who need administration of immunosuppressants - subjects who are allergic or sensitive to investigational products or its ingredients - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators

- subjects who cannot orally administer the investigational products - subjects who need administration of immunosuppressants - subjects who are allergic or sensitive to investigational products or its ingredients - subjects who have a history of drug and/or alcohol abuse within 52 weeks before screening - subjects who have been identified with uncontrolled concomitant diseases or conditions, including significant mental illness and social conditions, that may affect compliance with clinical trial procedures according to the determination of the investigators